Oxford Ledge
Search
BriaCell Therapeutics Corp. (NASDAQ: BCTX) is a biotechnology company trading at $3.54. Figures from SEC EDGAR and market feeds; updated 2026-10-11 00:46 UTC.
BriaCell is a biopharmaceutical company developing whole-cell cancer immunotherapies, including product candidates Bria-IMT and Bria-OTS. The company holds intellectual property protection through patents granted in multiple countries, including the United States, Japan, Australia, and New Zealand, with additional patent applications pending. BriaCell operates corporate offices in Canada and the United States, with research and development activities focused on clinical trials and innovative immunotherapeutic strategies in collaboration with external institutions.
Summarized from BriaCell Therapeutics Corp.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
| Quote | |
| Price | $3.54 |
| Volume | 24.1K shares |
BriaCell is a biopharmaceutical company developing whole-cell cancer immunotherapies, including product candidates Bria-IMT and Bria-OTS.
BCTX trades at $3.54, as of 2026-10-11.
BriaCell Therapeutics Corp.'s most recent SEC filing on record is a 8-K filed 2026-06-26. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings and public market data feeds, fetched 2026-10-11 00:46 UTC. This page is also available as JSON at /api/data?ticker=BCTX and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for BCTX and 5,000+ tickers.
Create a free account — keep BCTXGET /api/data?ticker=BCTX
This page as JSON via rel="alternate" · REST API docs · MCP server (62 tools) · llms.txt